Uysal, AyşeSoyer, Nur AkadÖzkan, MeldaŞahin, FahriVural, FilizTöbü, MahmutSaydam, Güray2020-12-012020-12-0120181300-01441303-6165https://doi.org/10.3906/sag-1611-97https://app.trdizin.gov.tr//makale/TWprNU1USXhNUT09https://hdl.handle.net/11454/66396Background/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractory multiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone. Materials and methods: Twenty-one R/R-MM patients who were treated with CFZ plus dexamethasone between October 2013 and January 2016 were screened. the patients were followed until March 2016 after CFZ treatment. Results: Ten (47.6%) of the patients were female and 11 (52.4%) of them were male. the median age was 62 (47–76) years. the median number of prior treatment lines was 3 (2–7). the median number of administered cycles of treatment for CFZ was 4 (1–10). the median overall response rate was 26.3%. the most common hematological adverse events were anemia and thrombocytopenia (38%). the most common nonhematological adverse event was fatigue (71.4%). One patient died because of a cerebrovascular event and 1 patient died because of pneumonia during the treatment period. the median duration of response rate and time to next therapy were 8 (7–9) and 3 (2–16) months, respectively. the median overall survival was 8 (0.5–33) months. Conclusion: Despite the small number of patients, our results suggest that CFZ provides acceptable responses in heavily pretreated R/R-MM patients.en10.3906/sag-1611-97info:eu-repo/semantics/openAccessCerrahiArticle4818083